Cited by 591Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, Antoni, Camacho, Luis H., Lopez-Berestein, Gabriel, Pavlov, Dmitri, Bulanhagui, Cecile A., Millham, Robert, Comin-Anduix, Begoña, Reuben, James M., Seja, Elisabeth, Parker, Charla A., Sharma, Amarnath, Glaspy, John A., Gomez-Navarro, Jesus·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.109

Open this paper in CoChat — free account

Abstract

Purpose: Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective immune responses to cancer in humans. A phase I trial was conducted to test the safety of CP-675,206. Patients and Methods: Thirty-nine patients with solid malignancies (melanoma, n = 34; renal cell, n = 4; colon, n = 1) received an intravenous (IV) infusion of CP-675,206 at seven dose levels. The primary objective was to determine the maximum-tolerated dose and the recommended phase II dose. Results: Dose-limiting toxicities and autoimmune phenomena included diarrhea, dermatitis, vitiligo, panhypopituitarism and hyperthyroidism. Two patients experienced complete responses (maintained for 34+ and 25+ months), and there were two partial responses (26+ and 25+ months) among 29 patients with measurable melanoma. There have been no relapses thus far after objective response to therapy. Four other patients had stable disease at end of study evaluation (16, 7, 7, and 4 months). Additionally, five patients had extended periods without disease progression (36+, 35+, 26+, 24+, and 23+ months) after local treatment of progressive metastases. Longer systemic exposure to CP-675,206 achieved in higher dose cohorts predicted for a higher probability of response. Conclusion: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.109

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 201–300 of 591

Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer
Acquavella, N., Kluger, H. M., Rhee, J., Farber, L. R., Tara, H., Ariyan, S., Narayan, D., Kelly, W. K., & Sznol, M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177a4ba · Cited by 51
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 51
Toxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 51
The Janus Face of Tumor Microenvironment Targeted by Immunotherapy
Buoncervello, M., Gabriele, L., & Toschi, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174320 · Cited by 50
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
Malas, S., Harrasser, M., Lacy, K. E., & Karagiannis, S. N. (2014) · Oncology Reports · doi:10.3892/or.2014.3275 · Cited by 50
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 50
Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?
Çetin, B., Berk, V., Ma, K., Afşar, B., Tufan, G., Özkan, M., Işikdoǧan, A., Beneklı, M., Çoşkun, U., & Buyukberber, S. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.09.001 · Cited by 49
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
Baik, C. S., Rubin, E. H., Forde, P. M., Mehnert, J. M., Collyar, D. E., Butler, M. O., Dixon, E. L., & Chow, L. Q. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3066 · Cited by 49
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine
Dangoor, A., Lorigan, P. C., Keilholz, U., Schadendorf, D., Harris, A. L., Ottensmeier, C. H. H., Smyth, J., Hoffmann, K. K. P., Anderson, R. J., Cripps, M., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0811-7 · Cited by 48
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 52
The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Cranmer, L. D., & Hersh, E. M. (2007) · Cancer Investigation · doi:10.1080/07357900701522315 · Cited by 47
Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies
Das, S., Camphausen, K. A., & Shankavaram, U. T. (2020) · Cancers · doi:10.3390/cancers12092476 · Cited by 47
Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma
Wang, E., Kang, D., Bae, K., Marshall, M. A., Pavlov, D., & Parivar, K. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.309 · Cited by 47
Self-citation
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
Menzies, A. M., & Long, G. V. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.027 · Cited by 48
Metastatic melanoma – a review of current and future drugs
Velho, T. R. (2012) · Drugs in Context · doi:10.7573/dic.212242 · Cited by 50
Clinical and Immunologic Basis of Interferon Therapy in Melanoma
Tarhini, A. A., & Kirkwood, J. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05073.x · Cited by 47
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 47
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
Chen, Y. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.08.005 · Cited by 47
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
Moore, T. V., Wagner, C. R., Scurti, G. M., Hutchens, K. A., Godellas, C. V., Clark, A. L., Kolawole, E. M., Hellman, L. M., Singh, N. K., Huyke‐Hernández, F. A., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2073-0 · Cited by 48
Synthesis and characterization of a novel biocompatible pseudo-hexagonal NaCa-layered double metal hydroxides for smart pH-responsive drug release of dacarbazine and enhanced anticancer activity in malignant melanoma
Asiabi, H., Yamini, Y., Alipour, M. A., Shamsayei, M., & Hosseinkhani, S. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.12.017 · Cited by 47
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
Guram, K., Kim, S. S., Wu, V. H., Sanders, P. D., Patel, S. H., Schoenberger, S. P., Cohen, E. E. W., Chen, S., & Sharabi, A. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00491 · Cited by 51
Melanoma in the elderly patient: relevance of the aging immune system
Hegde, U. P., Chakraborty, N. G., Kerr, P. E., & Grant-Kels, J. M. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.012 · Cited by 47
Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity
Lybaert, L., Vermaelen, K. Y., Geest, B. G. D., & Nuhn, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.009 · Cited by 46
RNA Vaccines in Cancer Treatment
Bringmann, A., Held, S. A. E., Heine, A., & Brossart, P. (2010) · BioMed Research International · doi:10.1155/2010/623687 · Cited by 45
Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy
Bauzon, M., & Hermiston, T. W. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00074 · Cited by 47
Immunotherapy for advanced melanoma: Fulfilling the promise
Gogas, H. J., Polyzos, A., & Kirkwood, J. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.006 · Cited by 47
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
Tarhini, A. A., & Kirkwood, J. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1583 · Cited by 44
Translatability scoring in drug development: eight case studies
Wendler, A., & Wehling, M. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-39 · Cited by 43
Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines
D, S. M. M., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 44
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
Tykodi, S. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48443 · Cited by 43
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Sharma, P., Sohn, J., Shin, S. J., Oh, D., Keam, B., Lee, H. J., Gizzi, M., Kalinka‐Warzocha, E., Vos, F. D., Ruscica, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1635 · Cited by 45
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 44
A microRNA profile of human CD8+ regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes
Jebbawi, F., Fayyad‐Kazan, H., Merimi, M., Lewalle, P., Verougstraete, J.-C., Léo, O., Romero, P. J., Burny, A., Badran, B. M., Martiat, P., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0218-x · Cited by 45
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
Ribas, A., Chesney, J. A., Gordon, M. S., Abernethy, A. P., Logan, T. F., Lawson, D. H., Chmielowksi, B., Glaspy, J. A., Lewis, K. D., Huang, B., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-236 · Cited by 42
Self-citation
Addressing the unmet need in lung cancer: The potential of immuno-oncology
Scagliotti, G. V., Bironzo, P., & Vansteenkiste, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.001 · Cited by 41
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays
Comı́n-Anduix, B., Gualberto, A., Glaspy, J. A., Seja, E., Ontiveros, M., Reardon, D., Renteria, R., Englahner, B., Economou, J. S., Gómez-Navarro, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0136 · Cited by 41
Self-citation
Melanoma Treatments: Advances and Mechanisms
Marzuka-Alcalá, A., Huang, L., Theodosakis, N., & Bosenberg, M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25019 · Cited by 43
Screening and antitumor effect of an anti‑CTLA‑4 nanobody
Wan, R., Liu, A., Hou, X., Lai, Z., Li, J., Yang, N., Tan, J., Mo, F., Hu, Z., Yang, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6131 · Cited by 42
Cancer immunotherapies: A hope for the uncurable?
Hamdan, F., & Cerullo, V. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140977 · Cited by 41
A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay
Chaudhary, R., Quagliata, L., Jermann, P. M., Alborelli, I., Cyanam, D., Mittal, V., Tom, W., Au-Young, J. K., Sadis, S. E., & Hyland, F. C. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.01 · Cited by 42
Immune Checkpoint Inhibitors and Neurotoxicity
Zhao, Z., Zhang, C., Zhou, L., Dong, P., & Shi, L. (2020) · Current Neuropharmacology · doi:10.2174/1570159x19666201230151224 · Cited by 39
The role of LncRNAs in tumor immunotherapy
Pan, X., Li, C., & Feng, J. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02872-3 · Cited by 40
Novel treatment strategies for malignant melanoma: A new beginning?
Kasper, B., D’Hondt, V., Vereecken, P., & Awada, A. H. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.11.007 · Cited by 39
The advances in immunotherapy for hepatocellular carcinoma
Zhang, F., & Li, Y. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.20 · Cited by 38
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma
Celis, E. (2007) · Cancer · doi:10.1002/cncr.22744 · Cited by 38
Predictive factors for immunotherapy in melanoma.
Teixidó, C., González‐Cao, M., Karachaliou, N., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.05.07 · Cited by 39
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
Jiang, D., Fyles, A., Nguyen, L. T., Neel, B. G., Sacher, A. G., Rottapel, R. K., Wang, B. X., Ohashi, P. S., & Sridhar, S. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26893 · Cited by 37
Overcoming immunological tolerance to melanoma: targeting CTLA-4
HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
Self-citation
Recent Advances in the Biology, Therapy and Management of Melanoma
Davids, L. M. (2013) · InTech eBooks · doi:10.5772/46052 · Cited by 38
Current and emerging treatment options for metastatic melanoma: a focused review
Nguyen, K., Hignett, E., & Khachemoune, A. (2020) · Dermatology Online Journal · doi:10.5070/d3267049551 · Cited by 38
CTLA-4 Blockade: Autoimmunity As Treatment
Kapadia, D., & Fong, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.012 · Cited by 36
Adverse Consequences of Immunostimulation
Ponce, R. A. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897920 · Cited by 35
Advances in targeted therapy and immunotherapy for melanoma (Review)
Qin, Z., & Zheng, M. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12115 · Cited by 36
Emerging therapies for melanoma
Katipamula, R., & Markovic, S. N. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.553 · Cited by 33
Tumor Vaccines for Breast Cancer
Anderson, K. S. (2009) · Cancer Investigation · doi:10.1080/07357900802574421 · Cited by 34
Molecular Markers for Colorectal Cancer
Wright, M., Beaty, J. S., & Ternent, C. A. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.01.014 · Cited by 33
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
Semmrich, M., Marchand, J.-B., Fend, L., Rehn, M., Remy, C., Holmkvist, P., Silvestre, N., Svensson, C., Kleinpeter, P., Deforges, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003488 · Cited by 33
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Goldman, J. W., Piha-Paul, S. A., Curti, B. D., Pedersen, K. S., Bauer, T. M., Groenland, S. L., Carvajal, R. D., Chhaya, V., Kirby, G., McGlinchey, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3016 · Cited by 33
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
Camacho, L. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.371 · Cited by 33
Self-citation
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 32
Malignant melanoma in elderly patients: biological, surgical and medical issues
RUSSO, A. E., Ferraù, F., Antonelli, G., Priolo, D., McCubrey, J. A., & Libra, M. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.961426 · Cited by 32
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
Freitas, C. M. T., Johnson, D. K., & Weber, K. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051295 · Cited by 32
Opportunistic autoimmune disorders
Kong, Y. M., Wei, W., & Tomer, Y. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05138.x · Cited by 33
Invariant natural killer T cells and immunotherapy of cancer
Molling, J. W., Moreno, M., van der Vliet, H. J., van den Eertwegh, A. J. M., Scheper, R. J., Blomberg, B. M. E. V., & Bontkes, H. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.025 · Cited by 32
Lack of Sprouty 1 and 2 enhances survival of effector CD8 + T cells and yields more protective memory cells
Shehata, H. M., Khan, S., Chen, E., Fields, P. E., Flavell, R. A., & Sanjabi, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808320115 · Cited by 31
New approaches in metastatic melanoma: biological and molecular targeted therapies
Lejeune, F. J., Rimoldi, D., & Speiser, D. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.701 · Cited by 32
Lentiviral Vectors: A Versatile Tool to Fight Cancer
Emeagi, P. U., Goyvaerts, C., Maenhout, S. K., Pen, J. J., Thielemans, K., & Breckpot, K. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040011 · Cited by 31
Retracted: Cancer immunotherapy: challenges and clinical applications
Xia, A., Xu, Y., & Lu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105852 · Cited by 30
Retracted
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 32
What does a modified-Fibonacci dose-escalation actually correspond to?
Penel, N., & Kramar, A. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-103 · Cited by 31
Learning the drug target‐likeness of a protein
Xu, H., Xu, H., Lin, M., Wang, W., Li, Z., Huang, J., Chen, Y., & Chen, X. (2007) · PROTEOMICS · doi:10.1002/pmic.200700062 · Cited by 31
Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD2 antibody in adoptive immunotherapy of cancer
Yamaguchi (1992) · International Journal of Oncology · doi:10.3892/ijo_00000182 · Cited by 31
Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance
Koon, H. B., & Atkins, M. B. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.1.79 · Cited by 30
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
Comı́n-Anduix, B., Sazegar, H., Chodon, T., Matsunaga, D. R., Jalil, J., von Euw, E., Escuin-Ordinas, H., BALDERAS, R. S., Chmielowski, B., Gómez-Navarro, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012711 · Cited by 29
Self-citation
Cytokine Therapy for Cancer
Kim‐Schulze, S., Taback, B., & Kaufman, H. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.011 · Cited by 30
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
Penel, N., Delord, J., Bonneterre, M.-E., Bachelot, T., Ray-Coquard, I. L., Blay, J., Pascal, L. B., Borel, C., Filleron, T., Adenis, A., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9224-x · Cited by 30
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 32
Modulation of CTLA-4 and GITR for Cancer Immunotherapy
Avogadri, F., Yuan, J. D., Yang, A. S., Schaer, D., & Wolchok, J. D. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_49 · Cited by 29
Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development
Eggermont, A. M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2377 · Cited by 29
Immune Regulatory Antibodies
Wolchok, J. D., Yang, A. S., & Weber, J. S. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3381 · Cited by 28
Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
von der Grün, J., Rödel, F., Brandts, C., Fokas, E., Gückenberger, M., Rödel, C. M., & Balermpas, P. (2019) · Cancers · doi:10.3390/cancers11040472 · Cited by 28
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
Bowman, K., & Kumthekar, P. (2018) · Future Oncology · doi:10.2217/fon-2017-0255 · Cited by 28
T Lymphocyte–Based Cancer Immunotherapeutics
Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27
Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy
Magyar, C. T. J., O'Kane, G. M., Aceituno, L., Li, Z., Vogel, A., Bruix, J., Mazzaferro, V., & Sapisochín, G. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00857 · Cited by 27
Melanoma vaccines: The problems of local immunosuppression
Polak, M. E., Borthwick, N., Jager, M. J., & Cree, I. A. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.017 · Cited by 27
Responses to immune checkpoint inhibitors in nonagenarians
Johnpulle, R. A. N., Conry, R. M., Sosman, J. A., Puzanov, I. J., & Johnson, D. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234572 · Cited by 27
Spray Equipment and Calibration
Hofman, V., & Solseng, E. (2004) · NDSU Repository (North Dakota State University) · Cited by 27
Mechanisms of T-cell inhibition: implications for cancer immunotherapy
Mittendorf, E. A., & Sharma, P. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.144 · Cited by 26
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28
Metastatic melanoma: the new era of targeted therapy
Guida, M., Pisconti, S., & Colucci, G. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645807 · Cited by 27
Targeted therapies in melanoma
Queirolo, P., & Acquati, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.009 · Cited by 26
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma
Moschos, S. J., & Kirkwood, J. M. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.020 · Cited by 26
Current topics in melanoma
Wolchok, J. D., & Saenger, Y. M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32801497c6 · Cited by 26
Tremelimumab for the treatment of malignant mesothelioma
Guazzelli, A., Hussain, M., Krstic–Demonacos, M., & Mutti, L. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1116515 · Cited by 25
Immunotherapy of melanoma
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells
Lotem, M., Machlenkin, A., Hamburger, T., Nissan, A., Kadouri, L., Frankenburg, S., Gimmon, Z., Elias, O., David, I. B., KUZNETZ, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3320 · Cited by 25
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
Viala, M., Vinches, M., Alexandre, M., Mollévi, C., Durigova, A., Hayaoui, N., Homicskó, K., Cuenant, A., Gongora, C., Gianni, L., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.473 · Cited by 24
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
Martinov, T., & Fife, B. T. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14106 · Cited by 28
Current State of Vaccine Therapies in Non–Small-Cell Lung Cancer
Romero, P. J. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.s.005 · Cited by 25

Authors: Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., Sharma, A., Glaspy, J. A., & Gomez-Navarro, J.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Medicine, Division of Hematology/Oncology; Surgery, Division of Surgical Oncology and UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Departments of Experimental Therapeutics, Melanoma Medical Oncology and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Pfizer Global Research and Development, Groton-New London, CT
ORCID: Ribas, Antoni
Camacho, Luis H.
Reuben, James M.
Sharma, Amarnath
Glaspy, John A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-10
Volume: 23
Issue: 35
Pages: 8968-8977
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.109
OpenAlex: W2163184777
Cited by: 591
References: 31
Citations by year: 2026: 4 · 2025: 1 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 21 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 32 · 2016: 33 · 2015: 29 · 2014: 25 · 2013: 38 · 2012: 27
FWCI: 22.08
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: CTLA-4 blockade, melanoma, antitumor immunity, peripheral tolerance, autoimmune adverse events, maximum tolerated dose, dose-limiting toxicity, complete response, renal cell carcinoma, colon cancer, immunotherapy safety
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colonic Neoplasms, Female, Humans, Immune Tolerance, Immunotherapy, Infusions, Intravenous, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Proteins, Neoplasms, Regression Analysis, Antigens, CD, T-Lymphocyte Subsets, Treatment Outcome, Antibodies, Blocking, Cancer Vaccines, MART-1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks